Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 14/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalapril SCHEMBL20817249 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL2719411 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL6155137 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL10390115 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL1650291 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL308603 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL825430 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9019924 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9019927 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2ACELMNAABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6068 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119769496-B | Hypertension blood sample protective agent, vacuum blood collection tube for hypertension blood sample detection and application | 河北鑫乐医疗器械科技股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| EP-4566590-A1 | TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF | Harbin Kanon Pharmaceutical Co., Ltd (CN) | 2025-06-11 | — | — | EP | claimed |
| CN-119769496-A | Hypertension blood sample protective agent, vacuum blood collection tube for hypertension blood sample detection and application | 河北鑫乐医疗器械科技股份有限公司 | 2025-04-08 | — | — | CN | claimed |
| EP-3965759-B1 | A TABLET FORMULATION COMPRISING LERCANIDIPINE AND ENALAPRIL | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2025-02-12 | — | — | EP | claimed |
| CN-119185217-A | Enalapril maleate tablet and preparation method thereof | 浙江海阁堂医药有限公司 | 2024-12-27 | — | — | CN | claimed |
| EP-3174529-B1 | WATER DISPERSIBLE MINI-TABLETS COMPRISING ENALAPRIL MALEATE FOR THE TREATMENT OF HYPERTENSION IN A PEDIATRIC POPULATION AND METHOD OF PREPARATION THEREOF | PHARMATHEN SA (GR) | 2024-12-11 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| WO-1994001093-A1 | CONTROLLED POROSITY OSMOTIC ENALAPRIL PUMP | MERCK & CO., INC. (US) | 1994-01-20 | — | — | WO | claimed |
| US-5225401-A | Endopeptidase inhibitors for congestive heart failure | E. R. SQUIBB & SONS, INC. (US) | 1993-07-06 | — | — | US | claimed |
| CN-1072602-A | Improve the enhanced dermal osmosis system of the local conveying of medicine | RICHARDSON VICKS INC (US) | 1993-06-02 | — | — | CN | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| EP-0527624-A2 | Use of a selective inhibitor of neutral endopeptidase and an angiotensin converting enzyme inhibitor in the preparation of a pharmaceutical for treating congestive heart failure | E.R. Squibb & Sons, Inc. (US) | 1993-02-17 | — | — | EP | claimed |
| EP-0280999-B1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING ANGIOTENSIN-CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1993-01-07 | — | — | EP | claimed |
| US-4898732-A | Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system | THE CLINIPAD CORPORATION (US) | 1990-02-06 | — | — | US | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |